STAT+: Competition for obesity drugs, clinical blind spots, and more news from ADA

STAT PlusNewsletters Competition for obesity drugs, clinical blind spots, and more news from ADA You’re reading the web edition of STAT’s ADA in 30 Seconds newsletter Manage alerts for this article Email this article Share this article By Elizabeth Cooney and Elaine ChenJune 7, 2026 Elizabeth Cooney[email protected]Liz covers cardiovascular and metabolic disease, asking why we’re not doing better or even losing ground against the world’s leading killer. Send tips on Signal at LizC.22.Elaine Chen[email protected]Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. You’re reading the web edition of STAT’s ADA in 30 Seconds newsletter, from the American Diabetes Association’s annual conference. Welcome to the third and final edition of STAT’s ADA in 30 Seconds newsletter.Advertisement Elaine Chen starts us off with updates on the competitive climate for obesity drugs and I’m relaying insights on eating disorders, new word on a BCG vaccine, and a clarification from ADA on Friday’s police incident. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In diabetes, Obesity, Pharmaceuticals, STAT+ Submit a correction requestReprints Elizabeth Cooney Cardiovascular Disease Reporter Liz covers cardiovascular and metabolic disease, asking why we’re not doing better or even losing ground against the world’s leading killer. Send tips on Signal at LizC.22. Elaine Chen National Biotech Reporter Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Newsletter Your morning rundown of the science, politics, and money driving biotech today Recommended Newsletters June 6, 2026 STAT Plus: Triple hormone receptors, a monthly obesity drug, and a bittersweet ending Newsletters June 5, 2026 STAT Plus: Newer GLP-1s, pushback on research cuts, and a protest Advertisement Newsletters April 20, 2026 STAT Plus: At AACR, a provocative use of CAR-T, Merck’s new thing and cancer’s geography problem Newsletters April 19, 2026 STAT Plus: AACR 2026: More strong data for Revolution Medicines’ KRAS drug Subscriber Picks